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Abstract
Background: The majority of incident hemodialysis (HD) patients initiate dialysis via catheters. We sought to
identify factors associated with initiating hemodialysis with a functioning arterio-venous (AV) access.
Methods: We conducted a retrospective chart review of all adult patients, age >18 years seeing a nephrologist
with a diagnosis of CKD stage 4 or 5 during the study period between 06/01/2011 and 08/31/2013 to evaluate the
placement of an AV access, initiation of dialysis and we conducted a survey of providers about the process.
Results: The 221 patients (56% female) in the study had median age of 66 years (interquartile range (IQR), 57–75)
and were followed for a median of 1.26 years (IQR 0.6–1.68). At study entry, 81%had CKD stage 4 and 19% had CKD
stage 5. By the end of study, 48 patients had initiated dialysis. Thirty-four of the patients started dialysis with a catheter
(1 failed and 10 maturing AVFs), 9 with an AVF and 5 with an AVG. During the study period, 61 total AV accesses were
placed (54 AVF and 7 AVG). A higher urinary protein/ creatinine ratio and a lower eGFR were associated with AV access
placement and dialysis initiation. A greater number of nephrology visits were associated with AV access creation but
not dialysis initiation. Hospitalizations and hospitalizations with an episode of acute kidney injury (AKI) were strongly
associated with dialysis initiation (odds ratio (OR) 13.0 (95% confidence interval (CI) 2.3 to 73.3, p-value = 0.004) and OR
6.6 (95% CI 1.9 to 22.8, p-value = 0.003)).
Conclusions: More frequent nephrology clinic visits for patients with a recent hospitalization may improve rates of
placement of an AV access. A hospitalization with AKI is strongly associated with the need for dialysis initiation.
Nephrologists may not be referring the correct patients to get an AV access surgery.
Keywords: Vascular access, CKD, Acute kidney injury, Hospitalizations, Hemodialysis
Background
Chronic kidney disease (CKD),including end-stage renal
disease (ESRD) requiring dialysis or transplantation, af-
fects 16.8% of adults in the United States (US) [1] and is
associated with an increased risk of death from cardio-
vascular disease [2]. Hemodialysis (HD) is the most
common form of renal replacement therapy in the US,
and thus, particular attention must be given to the
placement of a vascular access. Among all available
vascular access options, an arterio-venous fistula
(AVF) is preferred owing to its longevity and the few-
est associated complications. An arterio-venous graft
(AVG) is usually placed when a surgeon is unable to
place an AVF. Catheters are the least preferred as
their use has been shown to be a risk factor for
bacteremia and septicemia which correlates with an
increased risk of myocardial infarction, stroke, periph-
eral vascular disease and death [3].
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In order to increase the prevalence of AVFs in ESRD
patients, the National Kidney Foundation launched
the Fistula First Breakthrough Initiative (FFBI) in
2003, which increased AVF use in prevalent ESRD pa-
tients from 32% in 2003 to 56% in June 2010. During
the same period AVG use has decreased from 40% to
20%, however 82% of patients still initiated HD via a
catheter [4].
According to the United States Renal Data System
(USRDS), 80% of patients started HD via a catheter in
2013 [5]. Previous studies have shown pre-dialysis edu-
cation, pre-dialysis nephrology care, more frequent clin-
ical encounters and the presence of insurance as some
of the factors associated with the use of an AV access at
initiation of dialysis [6–9]. Whether or not a patient has
seen a nephrologist prior to starting dialysis may be sub-
ject to error depending on the data source [10]. Earlier
studies have also shown that only 50% of patients start
dialysis within a year of obtaining an AV access, suggest-
ing that nephrologists may not be recognizing which pa-
tients will need dialysis [11]. A study of ESRD in the
elderly found that among patients with CKD, those who
developed acute kidney injury (AKI) had a hazard ratio
of developing ESRD almost 5 times the hazard ratio of
those who didn’t develop AKI [12]. Thus, potentially one
of the biggest risk factors for progression may be diffi-
cult to predict.
As there is limited information available about patients
with late stage CKD and their specific barriers to AV ac-
cess placement, we studied all adult patients with CKD
stage 4 or 5, to evaluate the timeliness of AV access
placement and identify barriers to access placement and
factors associated with initiation of dialysis with or with-
out an AV access. We also surveyed nephrologists at our
institution to assess their perceptions of the access
placement process. We hypothesized that patients seen
by a nephrology fellow along with a faculty member
would be more likely to have an AV access placed.
Methods
Patients
We conducted a retrospective chart review of all adult
patients, age >18 years seeing a nephrologist with new
CKD stage 4 or 5 during the study period between June
1, 2011 and August 31, 2012. Patients were followed via
chart review until August 31, 2013. The patients (n = 31)
who had prior nephrologist follow-up for CKD stage 2
or 3 but were seen during the study period for the first
time with a diagnosis of CKD stage 4 or 5 were also in-
cluded and their day of nephrology visit with CKD stage
4 or 5 diagnosis was considered as the initial study visit.
Patients referred to the nephrology clinic at Montefiore
Medical Center (MMC) are managed either by faculty
nephrologists independently or in conjunction with
nephrology fellows. CKD stage 4 was defined as an
estimated glomerular filtration rate (eGFR) between
15–29 ml/min/1.73 m2 and CKD stage 5 was defined
as an eGFR <15 ml/min/1.73 m2 at study entry. GFR was
estimated using the Modification of Diet in Renal Disease
(MDRD) formula by the hospital’s laboratory using cre-
atinine measurements that are IDMS-traceable [13].
Patients were excluded from study (Fig. 1) if they
refused dialysis (n = 13), decided on peritoneal dialysis
(n = 11) or had an AV access placed before the study
period (n = 17). These 17 patients had a previous AV
access placed due to being post-transplant, transfers
from other centers or post-dialysis requiring AKI with
an AV access already placed. One additional patient
came for a second opinion, did not return to clinic and
was not included in this study. Patients were also excluded
Fig. 1 Study Flow Diagram
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if they were seeing a nephrologist (at Montefiore) for
CKD stage 4 or 5 prior to June 1, 2011.
Measurements
Data were extracted using the Clinical Looking Glass
(CLG) system (Emerging Health Information Technol-
ogy, Yonkers, New York), an interactive software ap-
plication developed at MMC that integrates clinical
and administrative datasets [14]. We used CLG to extract
demographic data, insurance status, race/ethnicity, body
mass index, smoking history, primary language (English,
Spanish), co-morbidities as coded by ICD-9 codes (pres-
ence or absence of diabetes mellitus, hypertension, con-
gestive heart failure, and peripheral vascular disease) and
laboratory data including hemoglobin, serum albumin and
creatinine which were measured within 90 days prior to
or 15 days after the initial nephrology visit for incident
stage 4 and 5 CKD. When multiple values were available,
the value closest to the clinic visit was used for analysis.
Electronic medical records were reviewed to get in-
formation regarding the number of nephrology visits,
eGFR at the time of the visits, CKD etiology, date and
eGFR at time of referrals, details of AV access surgery,
or if the patient was not referred for access surgery, the
reasons for non-referral. We collected data on the
number of AV access placed and on the initial vascular
access in patients starting HD. We also collected data
on hospitalizations and about whether the patients ex-
perienced an AKI episode (defined as a creatinine rise
>0.3 mg/dL) during the hospitalization. A patient was
considered lost to follow up if the patient was not seen
in any Montefiore clinic in last 6 months of the study
period. Data on death was obtained from hospital re-
cords and through linkage to the Social Security Ad-
ministration (SSA) mortality registry. This linkage
occurs in a continuous fashion by CLG. Data on dialy-
sis initiation was obtained by 1) review of electronic
medical records and 2) search for billings codes for
ESRD (585.6) or hemodialysis (39.95) or renal dialysis
status (V45.11). Data collection ceased at time of death
or dialysis whichever occurred first or at the time the
patient was lost to follow-up.
Nephrologists survey
We also conducted a web-based anonymous survey of all
of the nephrology faculty members (all ABIM certified in
Nephrology) and fellows (PGY 4 and 5) using REDCap
software [Einstein-Montefiore Institute for Clinical and
Translational Research grant support (UL1 RR025750)].
Questions and responses in the survey included:
1) In your opinion, what is the main limiting factor in









2) In your opinion, what is the main limiting factor in




 hospital system and appointments;
 patients;
 I am not sure.
For analysis we grouped patients’ refusal and non-
compliance as patient factors, nephrologists as nephrolo-
gist factor, hospital system and appointment and insur-
ance status as health care system factor, vascular
surgeon as vascular surgeon factor. From the chart re-
view, reasons for not getting an AV access placed were
categorized as nephrologist reasons, if there was no re-
ferral to vascular surgery noted in the chart; patient rea-
sons, if patient refused to undergo AV access surgery or
if there was a referral but patient did not make the ap-
pointment; hospital system and appointments if patients
were waiting for their appointment to be evaluated by
vascular surgeon or to undergo AV access surgery or un-
able to undergo surgery due to lack of insurance.
Statistical analysis
We first compared the characteristics of patients seen by
faculty alone versus with nephrology fellows using the
Mann Whitney test and chi-square tests as appropriate.
The primary outcome was AV access placement. We
assessed the associations of key variables with vascular
surgery referral, AV access placement and initiation of
dialysis separately using multivariable logistic regression.
Variables of interest included care by a renal fellow, the
number of nephrology visits, whether or not the patient
was hospitalized and whether or not the patient had an
AKI episode during the hospitalization. Due to the small
number of events, we used the variables of interest sep-
arately in models adjusted for possible confounders in-
cluding age, sex, race/ethnicity, diabetes mellitus, log
protein/creatinine ratio and baseline eGFR.
We created a categorical variable classifying patients
into 4 possible outcomes: 1) no access placed/ no dialy-
sis initiated, 2) access placed/ no dialysis initiated, 3) no
access placed, dialysis initiated and 4) access placed/dia-
lysis initiated. We then evaluated whether there were
any factors that differentiated these groups using chi-
square tests or ANOVA as appropriate. We then
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compared the reasons obtained from the nephrologist
survey to the chart review data using Chi Square tests.
All statistical analysis was done using STATA version
10.2, Texas, US. All mean values were reported with one
standard deviation. Two-sided p-value <0.05 was consid-
ered statistically significant. The study protocol was ap-
proved by the institutional review board of the Albert
Einstein College of Medicine. The need for informed
consent was waived due to the retrospective nature of
study involving chart review only. The study was con-
ducted in adherence with the Declaration of Helsinki.
Results
The 221 patients (56% female) in the study had mean
(± standard deviation) age of 64.8 ± 13.6 years and were
followed for a median of 1.26 years (IQR 0.6–1.68 years).
Out of the 221 patients, 81% had CKD stage 4 and 19% had
CKD stage 5 at study entry. Fourteen percent of pa-
tients (n = 31) had prior follow-up with CKD stage 2 or
3 but were seen during the study period for the first
time with CKD stage 4 (n = 30) or stage 5 (n = 1). The
mean eGFR at study initiation was 20.8 ± 6.4 ml/min/
1.73 m2. As expected, diabetes mellitus (30.8%) and
hypertension (25.8%) were the predominant etiologies
of CKD. Glomerular diseases, acute kidney injury and
multifactorial causes were identified in 4.1%, 4.5% and
4.9% of patients, respectively.
Patients seen by faculty members independently as com-
pared to patients seen in conjunction with fellows were
significantly older, predominantly female and less likely to
have Medicaid and more likely to have Medicare. The
mean hemoglobin and albumin was significantly higher
among faculty patients as compared to fellows’ patients,
whereas the mean serum creatinine and urinary protein/
creatinine ratios were significantly higher among the fel-
lows’ patients (Table 1).
A total of 94 patients (42.5%) were referred to vascular
surgery with a mean eGFR at the time of referral of 16.3 ±
5.5 ml/min/1.73 m2. Access surgery was done in 61
(27.6%) patients (55 AVF and 6 AVG) with mean eGFR of
14.3 ± 6.2 ml/min/1.73 m2 (Figs. 1 and 2). The median time
of referral to the surgeon from the initial nephrology study
visit was 28 days (IQR, 0–133) while the median time to
see the surgeon from the time of referral was 52 days
(IQR, 27–106). The median time to surgery after an ap-
pointment with the surgeon was 30 days (IQR, 15–85).
Factors associated with vascular surgery referral were
African-American race, a higher number of nephrology
clinic visits, lower eGFR and higher urine protein/ cre-
atinine ratio (Table 2). Being seen with a renal fellow
was not shown to be associated with vascular surgery re-
ferral. The only factors shown to be associated with the
placement of an AV access were a higher number of
nephrology clinic visits, a higher protein/creatinine ratio
and lower eGFR at entry to the study. Factors associ-
ated with initiation of dialysis were a higher urine protein/
creatinine ratio, a lower baseline eGFR and having a
hospitalization during follow-up or a hospitalization with
an AKI episode during follow-up. Of the 48 patients who
started dialysis, 44 of them had a hospitalization with an
AKI episode, compared to 4 such hospitalizations in 173
patients who did not start dialysis (p-value <0.001 for
comparison). The predominant reasons for not undergo-
ing an access surgery (n = 160) were as follows; 43% of pa-
tients were not referred for unknown reasons, 20% of
patients had stable eGFR or eGFR >25 ml/min/1.73 m2,
10% of patients refused and 7% of patients missed their
appointment.
Patients who started HD but were not referred for vas-
cular surgery were more likely to have diabetes mellitus,
lower hemoglobin, albumin and eGFR levels and higher
urinary protein/creatinine ratios compared to patients
who did not start HD and not referred. All the patients
who started HD and were not referred for vascular sur-
gery had had a hospitalization with an AKI episode com-
pared to only 52% of patients who did not start dialysis
and were not referred (p <0.001) (Table 3).
By the end of study, 48 patients had started HD with
mean eGFR of 9.0 ± 4.9 ml/min/1.73 m2 (Fig. 1). Of all the
patients started on HD, 30 patients (62.5%) saw a neph-
rologist for less than a year and 17 patients (35.4%) had
seen the nephrologist for <6 months. The mean time from
the study visit to hemodialysis was similar in patients with
initial nephrology visit with CKD stage 5 and CKD stage 4
(0.68 ± 0.5 years and 0.83 ± 0.5 years, p = 0.4).
In the survey of 17 out of 30 nephrologists at our insti-
tution (57% response rate), patient related factors were
thought to be the major limiting factor in vascular surgery
referral (88%) and AV access placement (41%). Chart re-
view revealed nephrologists to be the major limiting fac-
tors in 51% and 44% cases, respectively (Table 4).
Discussion
Our study shows that in patients with diagnosis of CKD
stage 4 or 5 at our institution, the majority of patients
initiate hemodialysis via catheters. This is especially true
in those who saw a nephrologist for less than a year
(86.6%) and those with CKD stage 5 at referral (87.5%).
Although a much higher proportion of patients with a
first nephrology visit with CKD 5 (41%) required dialysis
during the study period as compared to CKD 4 (18.3%),
the mean time to dialysis initiation was comparable in
both groups. Hence, it is important to promptly refer pa-
tients for AV access placement who are at high risk of
progression to ESRD needing hemodialysis. It is, how-
ever, hard for nephrologists to predict which patients
will require dialysis [11]. Tangri et al. and Landray et al.
have proposed predictive models which may be used to
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identify patients for ESRD progression [15, 16]. In our
late stage CKD population, hospitalizations and hospital-
izations with an AKI episode were strongly associated
with the need for dialysis suggesting that nephrologists
need to be vigilant with these patients and follow them
frequently in clinic.
During the study period, 57% of patients were not re-
ferred to vascular surgery and 72% of all patients didn’t
undergo AV access placement. During this short follow up
with a median number of 4 (IQR 2–8) [mean 5.4 ± 4.1]
nephrology visits, it appears difficult to achieve successful
placement of an AV access. Hence, late referrals to ne-
phrologists, limited follow-up time, and the nephrologists’
lack of prompt referrals to surgery all together resulted in
the predominant use of catheters as an initial vascular ac-
cess. In a study of vascular access placement, patients with
a late nephrology referral had only an 8% likelihood
of having AV access creation compared to 39% of pa-
tients with early referrals [17]. Even in patients who
had an AVF, many were not mature by the time the
patients started dialysis and the patients still required
a catheter (11 patients started with a catheter but had
an AVF which was either maturing (10) or failed (1)).
One factor associated with placement of a vascular
access was frequent nephrology visits, suggesting that
late stage CKD patients may require more frequent
clinical visits. We also found that nephrologists per-
ceive patients as the major limiting factor to vascular
access placement, however, our chart review showed
the nephrologist as a potential barrier. Our results
suggest the need to educate nephrologists on the im-
portance of being a leader in obtaining AV access.
Table 1 Baseline characteristics of study patients. Data presented as either number (percent) or mean (standard deviation) as
appropriate
Total (221) Faculty (141) Fellow (80) p-value
Age [years] 64.8 (13.6) 67.2 (12.9) 60.6 (13.7) <0.001
Female (%) 124 (56) 91 (64.5) 33 (41.2) 0.001
Mean BMI [Kg/m2] 30.4 (7.0) 30.7 (7.1) 29.7 (6.9) 0.14
Co-morbidities
Hypertension (%) 206 (93.2) 130 (92.2) 76 (95) 0.58
Diabetes Mellitus (%) 146 (66) 93 (65.9) 53 (66.3) 0.9
Congestive Heart Failure (%) 96 (43.4) 58 (41.1) 38 (47.5) 0.39
Peripheral Vascular Disease (%) 33 (14.9) 23 (16.3) 10 (12.5) 0.55
Race/ Ethnicity 0.06
White (%) 17 (7.7) 14 (9.9) 3 (3.7)
African-American (%) 68 (30.8) 49 (34.7) 19 (23.7)
Hispanic 107 (48.4) 63 (44.7) 44 (55)
Other 29 (13.1) 15 (10.6) 14 (17.5)
Primary Language
English (%) 164 (74.2) 108 (76.5) 56 (70) 0.3
Spanish (%) 51 (23.2) 30 (21.3) 21 (26.2) 0.4
Insurance
Medicaid (%) 77 (34.8) 33 (23.4) 44 (55) <0.001
Medicare (%) 70 (31.8) 54 (38.3) 16 (20) 0.006
Never smoker (%) 118 (53.4) 76 (53.9) 42 (52.5) 0.8
Hemoglobin, mean (SD) [gm/dL] 10.7 (1.8) 10.9 (1.8) 10.3 (1.8) 0.04
Albumin, mean [gm/dL] 3.8 (0.6) 3.96 (0.6) 3.53 (0.7) <0.001
Creatinine, mean [mg/dL] 2.88 (1.2) 2.7 (1.2) 3.18 (1.2) 0.005
Renal Clinic visit, mean 5.4 (4.1) 5.3 (4.2) 5.5 (4.1) 0.8
eGFR [ml/min/1.73 m2] at the study entry, median (IQR) 20.8 (6.4) 21.3 (6.2) 19.8 (6.5) 0.07
Urine albumin/creatinine ratio 0.78 (0.18, 3.73) 0.51 (0.13, 2.08) 2.64 (0.44, 5.31) <0.001
Follow up (years), median (IQR) 1.26 (0.6–1.68) 1.3(0.75–1.69) 1.2 (0.4–1.6) 0.1
Any hospitalization 155 (70.1) 89 (63.1) 66 (82.5) 0.002
Any hospitalization with acute kidney injury episode 136 (61.5) 74 (52.5) 62 (77.5) <0.001
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The drive to avoid catheters is due to increased risk of
bacteremia, metastatic infections, thrombosis, venous
stenosis, need of frequent interventions to maintain their
function, increased cost, anemia, cardiovascular events,
hospitalizations, and mortality [18]. According to a re-
cent study, creating early AV access may even have an
added benefit of decelerating the decline of eGFR in pa-
tients with CKD, delaying the onset of ESRD [19]. While
it is not clear what the physiologic mechanism of this
deceleration is, or if even the deceleration was simply
due to more attentive nephrology care for patients that
underwent an AV access procedure, the authors of that
study speculated that remote ischemic preconditioning
caused by the creation of vascular access, may stimulate
the release of humoral factors such as adenosine,
erythropoietin and nitric oxide that are renal protective
[19]. In order to reduce catheter use, planning for an
early placement of an AVF is crucial to its success due
to the need for maturation of veins and to account for
possible failure of maturation. KDOQI guidelines sug-
gested that patients should be referred to vascular sur-
geon for creation of an AVF when the eGFR is <25 ml/
min/1.73 m2 [20]. As per DOPPS II data, in countries
such as Australia/New Zealand, Germany, and Japan
50–72% of incident ESRD patients started HD with an
AVF compared to 16% in the US [21]. This study also
showed that countries such as Germany and Japan had
much faster referral times to see a surgeon compared to
Table 2 Odds ratio of vascular surgery referral and AV access placement
Vascular surgery referral (n = 94) AV access placement (n = 61) Initiated Dialysis (n = 48)
ORa 95% CI p-value ORa 95% CI p-value OR 95% CI p-value
Age, per year 0.99 0.96 to 1.02 0.33 0.97 0.94 to 1.00 0.06 0.98 0.95 to 1.01 0.27
African-American Race (compared to white) 4.65 1.00 to 21.6 0.05 1.10 0.27 to 4.46 0.89 0.72 0.15 to 3.43 0.68
Hispanic Ethnicity (compared to non-Hispanic white) 2.81 0.64 to 12.44 0.17 0.70 0.18 to 2.76 0.61 0.51 0.11 to 2.31 0.38
Diabetes Mellitus 1.29 0.58 to 2.88 0.53 0.91 0.40 to 2.06 0.82 1.76 0.66 to 4.71 0.26
Log urine protein/ creatinine ratio 1.45 1.13 to 1.86 0.003 1.36 1.05 to 1.75 0.02 1.72 1.28 to 2.32 <0.001
eGFR at the study entry 0.87 0.82 to 0.93 <0.001 0.89 0.83 to 0.94 <0.001 0.90 0.84 to 0.97 0.003
Patient seen with renal fellow 1.45 0.67 to 3.13 0.34 1.10 0.25 to 1.49 0.82 1.35 0.56 to 3.27 0.50
Number of nephrology visits 1.27 1.12 to1.45 <0.001 1.13 1.01 to1.25 0.03 1.02 0.92 to 1.14 0.68
Hospitalization during follow-up 0.97 0.41 to 2.29 0.94 2.46 0.94 to 6.4 0.07 13.0 2.3 to 73.3 0.004
AKI during hospitalization 0.78 0.35 to 1.72 0.53 1.84 0.79 to 4.28 0.26 6.6 1.89 to 22.8 0.003
aAll models adjusted for age, sex, race/ethnicity, diabetes mellitus, log urinary albumin/creatinine ratio and baseline eGFR. Renal fellow visit, number of renal visits,
number of hospitalization, and the presence of AKI during a hospitalization put in individually with the above adjusters. (abbreviations: OR-odds ratio;
CI-confidence interval)
Fig. 2 Flow Diagram showing vascular surgery referral and AV access placement
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Table 4 Reasons for non-placement of vascular access
Limiting Factors Vascular Surgery Referral AV Access placement
Nephrologist Survey Observed by chart Review p-value Nephrologist Survey Observed by chart review p-value
Patients 88a% 15% <0.001 41% 18% 0.01
Nephrologists 6% 51% <0.001 6% 44% <0.001
Health system problemsb 6% 2% 0.19 41% 11% <0.001
Vascular surgeon NA NA NA 0% 0% NA
Stable GFRc NA 27% NA NA 20% NA
Others NA 5% NA 12d% 8% 0.5
aPatient refusal (47%), patient non-compliance (29.4%) and patient not decided about modality of dialysis (11.8%); bHealth system problems include insurance
problems and hospital system and appointment problems including time delay in waiting for surgery or appointment. cIt was not known to be a barrier at the
time of survey hence was not included in survey; dActual answer: “I am not sure”; Abbreviation: NA-Not applicable
Table 3 Characteristics of patients who started dialysis compared to patients who had an AV access placed during the follow-up
period
Characteristic No HD, No referral
(n = 114)
Started HD, no
referral (n = 13)
No HD, Referred for
AV access (n = 59)
Started HD and Referred
for AV access (n = 35)
p-value
Age, mean (SD) 68.0 (13.3) 60.5 (15.5) 63.3 (13.2) 58.9 (11.7) 0.002
Female (%) 72 (63) 7 (53) 26 (44) 19 (54) 0.12
Mean BMI [Kg/m2] 31.0 (7.4) 28.7 (9.1) 29.5 (6.0) 30.4 (6.4) 0.47
Co-morbidities
Hypertension (%) 104 (91) 12 (92) 57 (97) 33 (94) 0.60
Diabetes Mellitus (%) 68 (60) 10 (77) 38 (64) 30 (86) 0.03
Congestive Heart Failure (%) 45 (39) 9 (69) 24 (41) 18 (51) 0.15
Peripheral Vascular Disease (%) 16 (14) 3 (23) 9 (15) 5 (14) 0.86
Race/ Ethnicity 0.15
White N (%) 11 (10) 3 (23) 2 (3) 1 (3)
African American(%)a 33 (29) 6 (46) 19 (32) 10 (29)
Hispanic N (%) 52 (45) 4 (31) 30 (51) 21 (60)
Other N (%) 18 (16) 0 8 (14) 3 (8)
Primary Language 0.74
English (%)a 82 (72) 12 (92) 44 (75) 26 (74)
Spanish (%)a 29 (25) 1 (8) 12 (20) 9 (26)
Never smoker (%) 67 (59) 4 (31) 30 (50) 17 (49) 0.45
Hemoglobin, mean (SD) [gm/dL] 11.1 (1.8) 9.2 (2.1) 10.5 (1.7) 10.5 (1.9) 0.001
Albumin, mean [gm/dL] 4.02 (0.55) 3.36 (0.68) 3.77 (0.63) 3.45 (0.59) <0.001
Creatinine, mean [mg/dL] 2.39 (0.80) 3.5 (1.93) 3.04 (1.00) 3.95 (1.46) <0.001
Hospitalization, N (%) 70 (61) 13 (100) 39 (66) 33 (94) <0.001
Renal Clinic visit, median (IQR) 4 (2 to 7) 2 (1 to 4) 6 (3 to 11) 3 (6 to 9) <0.001
eGFR [ml/min/1.73 m2] at the study
entry, median (IQR)
26 (21 to 28) 20 (16 to 27) 19 (15 to 25) 17 (12 to 20) <0.001
Hospitalization with AKI episode, N (%) 59 (52) 13 (100) 33 (56) 31 (89) <0.001
Urine albumin/creatinine ratio 0.27 (0.1 to 0.82) 3.83 (1.87 to 5.15) 1.48 (0.61 to 5.07) 4.35 (2.38 to 7.87) 0.22
Follow up (years), median (IQR) 1.2 (0.6–1.7) 0.6 (0.3–1.0) 1.3 (1.1–1.7) 1.3 (0.5–1.5)
aTotal may not add up to 100% due to missing values
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the US [21]. Interestingly, an AVF may not always be the
best initial access placed in some patients as previously
suggested by Kurella Tamura et al. and DeSilva et al. who
suggest that an AVG may be better for older patients [22,
23]. This is also suggested by our data as 11 patients
started dialysis with a catheter and a “maturing AVF”.
A study of 319 patients by Lopez-Vargas et al [8] rec-
ognized that late referral by a nephrologist is an import-
ant factor similar to our study. Similarly, the study by
Stehman-Breen et al [24] suggested that fewer nephrol-
ogy visits (<5) prior to initiation to dialysis was associ-
ated with decreased odds of permanent vascular access
at the initiation of dialysis. Both of these findings are
further consolidated by our observation in this study.
Our study provides further insight in to potential bar-
riers involved once a patient is seen by a nephrologist.
FFBI suggests educating and providing feedback to ne-
phrologists and vascular surgeons about their center spe-
cific data on vascular access placement and the catheter
rate in incident patients [25]. Documentation of discus-
sion about renal replacement therapy and plan for AV ac-
cess placement should be routine [25]. Other suggestions
include patient education and developing a hospital sys-
tem whereby patients with CKD could be identified early
and referred timely to nephrologist and/or vascular sur-
geon [25]. It is also important to identify patients with ad-
vanced kidney disease who are at risk of rapid progression
to ESRD and need prompt referral to surgeons. From our
study, a hospitalization with an AKI episode is one pos-
sible way to identify high risk patients. Models predicting
patients’ progression to ESRD [15, 16] may be helpful.
Appointing a dedicated vascular access nurse has shown
to increase the proportions of incident ESRD patients
starting HD with AVF from 56% to 75% [26]. Since the
implementation of FFBI, which was also later publicized
as “catheter last” and “not fistula only”, various quality im-
provement projects have been successful in improving AV
access placement in ESRD patients [27–29].
There are limitations to our study. The chart review
was performed retrospectively and thus we didn’t have
information on reasons for not referring to a surgeon
when not documented in chart. Our definition of an
AKI episode, a creatinine rise of 0.3 mg/dL, represents a
small decrement in kidney function in patients with ad-
vanced CKD which may introduce misclassification of
AKI. The survey of nephrologists had a 57% response
rate and is subject, like all surveys, to recall bias. We
also lacked information on patients who may have initi-
ated HD at other institutions or at an outpatient HD
unit and were never seen at our institution thereafter.
However, Montefiore Medical Center is the largest pro-
vider of care to patients in the Bronx and provides care
to over 500,000 of the 1.4 million individuals living in
the Bronx. Our ascertainment of deaths was limited by
potential time lag from the use of SSA data. Finally, it is
a single center study with small numbers. However,
there are several strengths to our study. These include a
detailed chart review, linkage to mortality data, and pro-
spectively collected data on Nephrologists’ attitudes
about vascular access placement.
Conclusions
In conclusion, despite the knowledge that starting HD
with an AV access is optimal for patient care and sur-
vival, we found that late referral to vascular surgeons
continue to be a major obstacle in obtaining timely AV
access. Earlier referral to nephrologists and surgeons
may improve rates of placement of vascular access. In
addition, nephrologists may not be referring the correct
patients to get an AV access surgery. A hospitalization
with AKI is strongly associated with the need for dialy-
sis in patients with CKD stages 4 and 5. However, it is
hard for nephrologists to predict AKI. More frequent
nephrology clinic visits for patients with a recent
hospitalization may improve rates of placement of an
AV access, as the number of nephrology visits was the
only easily modifiable factor associated with increased
likelihood of an AV access placement.
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